BCL2 and mantle cell lymphoma: Therapeutically, selective inhibition of BCL-2 has been achieved with the BH3 mimetic, venetoclax (ABT-199), resulting in high response rates in certain lymphoid malignancies including chronic lymphoid leukemia (CLL) and mantle cell lymphoma (MCL)11,12.